It is demonstrated that integrated Perturb-seq experiments spanning diverse contexts enable hypotheses about gene function specific to tissue types or cancer subtypes – suggesting large-scale, genome-wide datasets would offer invaluable insight into the highly context-dependent nature of cancer biology.
Abstract
Background CRISPR-mediated viability assays in diverse cancer cell lines have informed cancer biology and precision medicine, but cell fitness is not the only cancer-relevant phenotype. Gene expression profiling provides insight into cellular stress, inflammation, and differential state, while still identifying activation of cell-death pathways. Perturb-seq allows scalable functional genomics screening of expression phenotypes at single-cell resolution, however existing datasets cover only a small number of work-horse cell lines. Results We produced a proof-of-concept Perturb-seq dataset targeting 100 genes in 16 diverse cancer cell lines. In the process, we established methods to address single-cell technical artifacts, identified Cas9-mediated chromosomal aberrations and assessed screen quality. Even with a limited library, we observed common signatures of deleting essential genes as well as context-specific responses based on intrinsic genomic properties of the models. For example, we inferred a previously undescribed relationship between dependence on the ER-golgi transport gene immediate early response 3 interacting protein 1 (IER3IP1) and oxidative stress, demonstrating the potential of integrated Perturb-seq for hypothesis generation. Conclusions We established a framework for building a comprehensive map of post-perturbational transcriptional phenotypes using parallel Perturb-seq experiments across multiple cell lines. We demonstrated that integrated Perturb-seq experiments spanning diverse contexts enable hypotheses about gene function specific to tissue types or cancer subtypes – suggesting large-scale, genome-wide datasets would offer invaluable insight into the highly context-dependent nature of cancer biology.
Perturb-ME, along with agentic interpretation, provide a scalable framework for comprehensive functional discovery from phenotype-enriched genetic screens and combines genome-scale CRISPR screening, phenotype-based enrichment and multimodal single-cell profiling.
Han-Chen Wang, Jiacheng Gu, Chris J. Frangieh et al.· bioRxiv· 0 citations
Genome-wide CRISPR screens have systematically identified genes required for cancer cell survival, yet these studies are typically performed under standardized conditions that do not fully recapitulate the physiological stresses encountered within the tumor microenvironment. In a recent issue of Nature Genetics, Cherui...
Zihan Ning, Guangchuan Wang· Cancer Research· 0 citations
Key methodological steps for achieving high-efficiency lentiviral transduction and selection are described, enabling the successful application of EPIKOL CRISPR screens in chemoresistant TNBC models.
O. Yedier-Bayram, Elif Ayca Guvener, T. Bagci-Onder· Journal of Visualized Experi...· 0 citations
It is proposed that integrating precise editing, in vivo screening, single-cell multi-omics, and emerging artificial intelligence (AI)-assisted design may provide information and a design basis for future combined strategies that simultaneously target vulnerabilities in senescent cells and malignant populations.
Bo Fan, Aiwei Wu, Xue Pan et al.· Ageing and Cancer Research &...· 0 citations
It is argued that the major value of organoid‐based CRISPR screening lies in its ability to identify functionally actionable cancer vulnerabilities in a patient‐contextualized model, while also introducing methodological challenges that must be addressed for robust clinical translation.
J. du Plessis, Aadilah Omar· Cancer Medicine· 0 citations
The N-glycosylation module is demonstrated as a recurrent hub of context-dependent genetic interactions and combinatorial CRISPR screening as a scalable approach for identifying therapeutic targets and resistance mechanisms in oncogene-driven cancers.
Subin Kim, Chen-Chu Lin, Sabriyeh Alibai et al.· Clinical Cancer Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.